Arcus Biosciences (RCUS) Current Deferred Revenue (2017 - 2026)

Arcus Biosciences' Current Deferred Revenue history runs 10 years deep, the most recent figure standing at $79.0 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue rose 9.72% year-over-year to $79.0 million; the TTM figure through Mar 2026 stood at $79.0 million (up 9.72% YoY), while the FY2025 annual figure was $78.0 million, down 75.55% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $79.0 million, up from $78.0 million in the prior quarter.
• The five-year high for Current Deferred Revenue was $429.0 million in Q3 2023, with the low at $35.0 million in Q2 2023.
• The 5-year median for Current Deferred Revenue is $97.0 million (2022), against an average of $168.6 million.
• The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue jumped 834.29% in 2024, then sank 80.33% in 2025.
• Arcus Biosciences' Current Deferred Revenue stood at $97.0 million in 2022, then tumbled by 63.92% to $35.0 million in 2023, then soared by 811.43% to $319.0 million in 2024, then plunged by 75.55% to $78.0 million in 2025, then rose by 1.28% to $79.0 million in 2026.
• Business Quant data shows RCUS's Current Deferred Revenue at $79.0 million in Q1 2026, $78.0 million in Q4 2025, and $105.0 million in Q3 2025.